Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

Xoma

450 Posts
Pagina: «« 1 2 3 4 5 6 ... 23 »» | Laatste | Omlaag ↓
  5. [verwijderd] 17 januari 2007 17:29

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    psycho-pharma schreef:

    XOMA and Schering-Plough Add New Programs to Antibody Collaboration

    XOMA Ltd. (Nasdaq:XOMA) announced that Schering-Plough Corporation (NYSE:SGP) exercised its right to initiate additional discovery and development programs under their collaboration for therapeutic antibody products. XOMA has received up-front payments for each of the additional collaboration programs and will also receive research funding for each project as well as success based milestones and royalties on the sale of any products that result from the collaboration.

    "We have made significant progress on the first product program since its initiation with Schering-Plough in mid-2006," said Jack Castello, chairman of the board, president, and chief executive officer of XOMA. "We look forward to advancing the new programs in a similar high quality and expedited manner."

    About the XOMA-Schering-Plough Collaboration

    On May 23, 2006, XOMA announced the initiation of a collaboration with Schering-Plough Corporation through its research and development arm, Schering-Plough Research Institute, for therapeutic monoclonal antibody discovery and development. Under the agreement, XOMA is responsible for discovering therapeutic antibodies against multiple targets selected by Schering-Plough. Other XOMA activities are expected to include preclinical studies to support regulatory filings, cell line and process development, and production of antibodies for initial clinical trials. Schering-Plough will make up-front and milestone payments to XOMA, fund XOMA's R&D activities related to the agreement, and pay royalties to XOMA on sales of products resulting from the collaboration.

    STAR erbij.....
    cws.huginonline.com/C/132631/PR/20060...
    gr.
  6. [verwijderd] 18 januari 2007 12:18

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Zacks Analyst Blog Highlights: Xoma, Genentech, Schering-Plough, LabCorp and Quest Diagnostics
    Business Wire - January 18, 2007 06:00

    CHICAGO, Jan 18, 2007 (BUSINESS WIRE) -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Xoma, Inc. (Nasdaq: XOMA), Genentech (NYSE: DNA), Schering-Plough (NYSE: SGP), LabCorp (NYSE: LH) and Quest Diagnostics (NYSE: DGX).

    See the latest posts to the Analyst Blog by visiting: at.zacks.com/?id=2673

    Here are highlights from Wednesday's Analyst Blog:

    Momentum at XOMA

    Xoma, Inc. (Nasdaq: XOMA) is picking up momentum in early 2007, with three positive developments in the last week. On January 9, 2007 the company initiated a phase I/II trial with Neuprex on allogenic stem cell transplant patients. Xoma remains committed to bringing Neuprex to the market in the U.S. through a combination of in-house and investigator sponsored trials (ISTs). Safety and pharmacokinestic data collected from this phase I/II trial in HSCT should help management plan additional trials potentially in the radiation protection under the U.S. government's biodefense efforts.

    On January 10, 2007, Genentech (NYSE: DNA) reported sales of both Raptiva and Lucentis above expectations. Genentech pays a royalty to Xoma on sales of both drugs. We have revised our earnings model based on the stronger-than-expected sales of Raptiva and Lucentis.

    Most recently, on January 17, 2007, Xoma signed a second collaboration with development partner Schering-Plough (NYSE: SGP), resulting in an upfront milestone payment. Xoma has not disclosed the upfront milestone fees captured from this collaboration, just that the total deal before back-end royalties on product sales is between $25 and $75 million. Using its extensive collection of phage display libraries and optimization technologies, Xoma will discover therapeutic antibodies against one or more targets selected by Schering-Plough. Xoma may also utilize its proprietary Human Engineering technology to humanize antibody candidates generated by hybridoma techniques. During the fourth quarter of 2006, both parties continued with pre-clinical studies. We expect an announcement of the first target to be made soon.

    Slow LabCorp Ramp-Up

    The UNH contract could produce volatility for LabCorp (NYSE: LH), given the possible slower-than-expected ramp-up. Stock buybacks remain a focal point for cash use and our estimates go up on an increased buyback outlook. At 18x our increased 2007 $3.91 EPS estimate, a premium to Quest Diagnostics' (NYSE: DGX) 1.3x 2007 P/E/G, our target moves to $70.00.

    With the integration of Dynacare and Dianon complete, the company now expects to benefit through cost savings. LabCorp expects these acquisitions to result in a cost savings of about $30 million on a pre-tax basis by mid 2007. The company outlined (as part of a strategic plan) to restructure LH sites over the next two years based on the Dianon model. Management believes that Dianon, a leader in anatomical pathology testing, is more efficiently run and provides better customer service.

    See the latest posts to the Analyst Blog by visiting at.zacks.com/?id=2645

  10. gustaaf1e 16 juli 2007 15:14

    • gustaaf1e

      Lid sinds: 01 jan 2000

      Laatste bezoek: 06 feb 2025

    • Aanbevelingen

      Ontvangen: 54

      Gegeven: 1

    •    Aantal posts: 1.656

    Nieuws van Xoma.
    G

    Xoma Initiates Phase I U.S. Trial In Type 2 Diabetes For XOMA 052 - Quick Facts

    (RTTNews) - Xoma Ltd. (XOMA) on Monday revealed the initiation of Phase I clinical testing of product candidate XOMA 052, a potent monoclonal antibody targeting Interleukin-1 beta, in patients with Type 2 diabetes. The company stated that the U.S.-based study is designed to assess the safety and pharmacokinetics of XOMA 052. The company plans to begin a European-based Phase I clinical trial of XOMA 052 in Type 2 diabetes patients later in 2007.

    Commenting on the initiation of the study, Jack Castello, chairman of the board, president and chief executive officer of XOMA, said, ''XOMA 052, developed by XOMA using XOMA's antibody discovery and Human Engineering technologies and capabilities, offers the promise of improved therapy for major medical needs. We are pleased to be able to advance XOMA 052 to the clinic and look forward to evaluating options for its broader clinical development.''

    For comments and feedback: contact editorial@rttnews.com
  13. gustaaf1e 25 juli 2007 22:05

    • gustaaf1e

      Lid sinds: 01 jan 2000

      Laatste bezoek: 06 feb 2025

    • Aanbevelingen

      Ontvangen: 54

      Gegeven: 1

    •    Aantal posts: 1.656

    Heb ook nergens een reden voor deze daling kunnen vinden. Misschien koers drukken voor overname? Hoop het niet, want op termijn veel beter perspectief voor dit aandeel.
    Maar de bodem lijkt nu wel bereikt.

    G
  15. gustaaf1e 8 augustus 2007 15:16

    • gustaaf1e

      Lid sinds: 01 jan 2000

      Laatste bezoek: 06 feb 2025

    • Aanbevelingen

      Ontvangen: 54

      Gegeven: 1

    •    Aantal posts: 1.656


    XOMA: To Present At IBC Drug Discovery Conference @ 08:30 ET

    Company representatives of XOMA LTD (NasdaqNM: XOMA) will be presenting at the IBC 12th Annual Drug Discovery & Development of Innovative Therapeutics World Congress today. The Company's presentation is scheduled to begin at 08:30 ET.

    Expected Speaker(s):

    Mary Haak-Frendscho, Ph.D., Vice President, Preclinical R&D, XOMA (US) LLC

    Misc Releated Info:

    ** Original Confirmation

    ** Conference Information:

    IBC 12th Annual Drug Discovery & Development of Innovative Therapeutics World Congress

    The event will focus on scientific innovations, new approaches, and business strategies that can help companies learn how to accelerate movement of compounds into the clinic.

    Conference Dates: 08/05/2007-08/09/2007

    World Trade Center Boston and Seaport Hotel

    Boston, MA


    G
  18. gustaaf1e 9 augustus 2007 15:03

    • gustaaf1e

      Lid sinds: 01 jan 2000

      Laatste bezoek: 06 feb 2025

    • Aanbevelingen

      Ontvangen: 54

      Gegeven: 1

    •    Aantal posts: 1.656


    Q2 resultaten Xoma.
    G

    Xoma Q2 Loss Per Share Flat With Prior Year Despite Higher Revenues - Update

    (RTTNews) - Wednesday evening, biopharmaceutical company Xoma Ltd. (XOMA) revealed its financial results for the second quarter, reporting loss per share that remained flat with the prior-year period on higher research and development costs, despite an increase in revenues.

    The Berkeley, California-based company's net loss for the second quarter was $8.34 million or $0.06 per share compared to net loss of $5.92 million or $0.06 per share in the prior-year quarter. On average, seven analysts polled by First Call/Thomson Financial expected the company to report loss of $0.08 per share for the quarter.

    Shares used in computing net loss per share for the quarter was 131.69 million compared to 96.66 million in the prior-year quarter.

    Total revenues for the quarter rose to $14.14 million from $7.51 million in the previous-year quarter. Wall Street analysts expected the company to report revenues of $12.52 million in the year-ago period.

    The company attributed the growth in revenues to increases in royalty revenues from Genentech's Lucentis, which began in June last year, and Genentech's Raptiva, as well as increased activities in its contracts with Aveo Pharmaceuticals, Inc., Schering-Plough Research Institute, Takeda Pharmaceutical Company Limited and the National Institute of Allergy and Infectious Diseases.

    License and collaborative fee revenues declined to $0.13 million from $0.73 million for the same period of last year. These revenues include upfront payments related to the outlicensing of the company's products and technologies, as well as other collaborative arrangements. Contract revenues rose to $9.75 million from $4.68 million a year ago, reflecting an increase resulting primarily from the company's arrangements with increased activities in its contracts with Aveo Pharmaceuticals, Inc., Schering-Plough Research Institute and Takeda Pharmaceutical Co. Limited. Royalties more than doubled to $4.26 million from $2.10 million a year ago, reflecting increases in royalty revenues from Genentech's Lucentis, which began in June of 2006, and Genentech's Raptiva.

    Research and development expenses rose to $17.32 million from $12.10 million in the previous-year quarter, reflecting increases in spending on the company's July 2006 contract with NIAID, its contract with Aveo, internal development of XOMA 052 and XOMA 629 as well as collaboration with Schering-Plough. General and administrative expenses remained flat with the year-ago period at $4.4 million.

    Loss from operations for the quarter narrowed to $7.53 million from $8.98 million in the year-ago period, reflecting higher revenue partially offset by an increase in research and development costs.

    Interest expense for the quarter declined to $1.2 million from $2.7 million in the year-ago period. The company noted that interest expense in the quarter consisted primarily of $0.3 million from Novartis and $0.8 million of interest payable on the company's loan from Goldman Sachs Specialty Lending Holding Inc.

    Cash, cash equivalents and short-term and long-term investments at June 30, 2007 declined to $24.0 million from $46.4 million at December 31, 2006. The company noted that the decrease primarily reflects cash used in operations of $15.2 million for the first six months of 2007, and includes a one-time payment of $5.2 million in additional interest on the convertible notes and $1.4 million related to the semi-annual interest payment on the convertible notes. Additionally, cash was used for fixed asset purchases of $3.8 million and for principal payments on the Goldman Sachs term loan of $4.7 million.

    For the six months, the company's net loss narrowed to $24.27 million or $0.20 per share from $26.52 million or $0.29 per share in the prior-year period.

    Total revenues for the half year rose to $26.39 million from $13.12 million in the similar period of the previous year.

    XOMA closed Wednesday's regular trading session at $2.17, up $0.12 or 5.85% on a volume of 2.03 million shares.

    For comments and feedback: contact editorial@rttnews.com

  19. gustaaf1e 9 augustus 2007 15:06

    • gustaaf1e

      Lid sinds: 01 jan 2000

      Laatste bezoek: 06 feb 2025

    • Aanbevelingen

      Ontvangen: 54

      Gegeven: 1

    •    Aantal posts: 1.656

    Xoma blijft aan de weg timmeren.
    G

    XOMA: To Present At Canaccord Adams Global Growth Conference @ 08:30 ET

    Company representatives of XOMA LTD (NasdaqNM: XOMA) will be presenting at the Canaccord Adams 27th Annual Global Growth Conference today. The Company's presentation is scheduled to begin at 08:30 ET.

    Expected Speaker(s):

    David Boyle, Chief Financial Officer

    Misc Releated Info:

    ** Original Confirmation

    ** Conference Information:

    Canaccord Adams 27th Annual Global Growth Conference

    The event will bring together innovative small- to mid-cap companies and institutional investors to share knowledge, discuss emerging trends, build relationships, identify opportunities and ignite global ideas for growth.

    Conference Dates: 08/07/2007-08/09/2007

    The InterContinental Hotel

    Boston, MA

    Phone: (617) 371-3842

    Email: nadine.miller@canaccordadams.com

  20. [verwijderd] 28 augustus 2007 14:23

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Pre market up:60 cents

    XOMA Licenses Antibody Technology to Pfizer
    Tuesday August 28, 8:05 am ET
    Initial Payment to XOMA of $30 Million

    BERKELEY, Calif., Aug. 28, 2007 (PRIME NEWSWIRE) -- XOMA Ltd. (NasdaqGM:XOMA - News) today announced that it has licensed to Pfizer Inc., the world's largest research-based biomedical and pharmaceutical company, non-exclusive, worldwide rights to XOMA's patented bacterial cell expression (BCE) technology for phage display and other research, development and manufacturing of antibody products.
    ADVERTISEMENT


    Under the terms of the agreement, XOMA will receive an upfront, non-dilutive cash payment of $30 million and milestone, royalty and other fees on future sales of all products subject to this license, including products currently in late-stage clinical development.

    Steven Engle, Chief Executive Officer and President of XOMA, said, ``This agreement provides clear validation of XOMA's antibody research and affirms XOMA's ability to capitalize on the value of our patented technologies. We continue to execute our strategy of using our technologies to generate high-margin revenue in support of our programs, including our proprietary product pipeline. We are very pleased that Pfizer has chosen to incorporate our BCE technology into their global drug development effort, and we look forward to what we anticipate will be a mutually beneficial relationship.

    ``BCE is an enabling technology for antibody phage display discovery and for the manufacture of bacterially expressed therapeutic antibody products,'' Mr. Engle continued. ``It is a proven technology for commercially significant therapeutic antibodies as demonstrated by the approval of LUCENTIS(r) for wet age-related macular degeneration. With more than 45 license agreements in place, BCE continues to be a seminal enabling technology in antibody discovery and production.''

    XOMA has licensed its BCE technology to many major pharmaceutical and biotechnology companies, including Merck & Co., Inc., Centocor, Inc. and Alexion Pharmaceuticals, Inc. for use in the development and manufacturing of marketed and investigational therapeutic antibody products. Under a license agreement with Genentech, Inc., XOMA currently receives royalties for their marketed therapeutic antibody product, LUCENTIS(r) which has been approved for the treatment of wet age-related macular degeneration since 2006. LUCENTIS(r) (ranibizumab) is an antibody fragment to Vascular Endothelial Growth Factor (VEGF). BCE technology is also employed for the production of CIMZIA (certolizumab, CDP-870), UCB S.A.'s anti-TNF (tumor necrosis factor) alpha antibody fragment, which has been submitted for regulatory approval for Crohn's disease. CIMZIA has had positive results in two Phase III trials in rheumatoid arthritis and in one mid-stage clinical trial in psoriasis.

    XOMA plans to update 2007 revenue guidance to reflect the new agreement when it announces third quarter 2007 results.

    Bacterial Cell Expression Technology

    Bacterial cell expression technology (BCE) is an enabling technology used to discover and screen, as well as develop and manufacture, recombinant antibodies for commercial purposes. BCE is also a key technology used in multiple systems for high-throughput screening of antibody domains. Expression of antibodies by phage display technology, for example, depends on the expression and secretion of antibody domains from bacteria as properly folded, functional proteins.

    XOMA scientists were the first to demonstrate the secretion of antibody domains directly from the bacterial cells as fully functional, properly folded molecules. XOMA has received ten U.S. patents to date relating to aspects of its BCE system, including six patents that broadly cover the secretion of immunoglobulins from bacteria, including antibody fragments such as Fab and single-chain antibodies. Corresponding foreign patents have also been granted. XOMA's intellectual property estate is applicable to the practice of antibody phage display and other antibody screening applications.

    About XOMA

    XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies, with a therapeutic focus that includes cancer and immune diseases. XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Merck Serono S.A.) to treat moderate-to-severe plaque psoriasis, and LUCENTIS(r) (ranibizumab injection), a monoclonal antibody product marketed worldwide (by Genentech and Novartis AG) to treat neovascular (wet) age-related macular degeneration.

    The company has built a premier antibody discovery and development platform that includes access to seven of the leading commercially available antibody phage display libraries and XOMA's proprietary Human Engineering(tm) and bacterial cell expression technologies. More than 45 companies have signed BCE licenses. XOMA's development collaborators include Lexicon Pharmaceuticals, Inc., Novartis, Schering-Plough Research Institute and Takeda Pharmaceutical Company Limited. With a fully integrated product development infrastructure, XOMA's product development capabilities extend from preclinical sciences to product launch. For more information, please visit the company's website at www.xoma.com.

    P.

450 Posts
Pagina: «« 1 2 3 4 5 6 ... 23 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.481
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.194
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.502
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.647
Aedifica 3 901
Aegon 3.258 322.648
AFC Ajax 538 7.086
Affimed NV 2 6.287
ageas 5.844 109.885
Agfa-Gevaert 14 2.048
Ahold 3.538 74.292
Air France - KLM 1.025 34.991
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.319
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.812
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.709
AMG 971 133.045
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 482
Antonov 22.632 153.605
Aperam 92 14.905
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.559
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.715
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.078
ASML 1.766 105.980
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 469
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.609
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390